Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.

Related Videos
Expert on breast cancer
Experts on BTC
Experts on BTC
Expert on CSCC
Experts on AML
Expert on AML
Experts on CRC
Expert on CRC
Related Content

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

Study Shows Women Over Age 65 With Low-risk Breast Cancer Could Skip Postoperative Radiation Therapy

March 9th 2023

Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

September 8th 2022

FDA Approval Sought for Cosibelimab in Metastatic or Locally Advanced CSCC

March 2nd 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

Study Shows Women Over Age 65 With Low-risk Breast Cancer Could Skip Postoperative Radiation Therapy

March 9th 2023

Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

September 8th 2022

FDA Approval Sought for Cosibelimab in Metastatic or Locally Advanced CSCC

March 2nd 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

March 6th 2023

Study Shows Women Over Age 65 With Low-risk Breast Cancer Could Skip Postoperative Radiation Therapy

March 9th 2023

Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

September 8th 2022

FDA Approval Sought for Cosibelimab in Metastatic or Locally Advanced CSCC

March 2nd 2023

FDA Approval Sought for Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

February 28th 2023